|
Acute lymphocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To verify a linkage between c-myb and NmU, their mRNA levels were quantitated using real-time polymerase chain reaction in primary acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), as well as normal hematopoietic cells.
|
15187020 |
2004 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SPP1 skeletal development module appears in human normal adjacent tissues (COL11A1_1 activation; COL10A1 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2 activation); signal module appears in human normal adjacent tissues (COL11A1_1, CXCL13, MMP11, SPINK1 activation; COL10A1, COL3A1 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2, MMP12 activation; CDH3, CXCL13, GREM1_2, MMP11, SPINK1 inhibition); biological regulation module appears in human normal adjacent tissues (CXCL13, MKI67, PYCR1 activation; NEK2, SPDEF, TOP2A_2, TOX3_1 inhibition), whereas in lung adenocarcinoma (HMGB3, MKI67, NMU, PYCR1, TOX3_2 activation; CXCL13, SPDEF, TOP2A_2 inhibition); sequence variant module appears in human normal adjacent tissues (COL11A1_1, MKI67, MMP11 activation; ASPM, COL10A1, COL3A1, NEK2, TMPRSS4, TOP2A_2 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2, HMMR, MKI67, MMP12 activation; ABCC3, ASPM, CDH3, MMP11, TOP2A_2 inhibition).
|
19949890 |
2010 |
|
Albuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure.
|
30220432 |
2018 |
|
Alcohol Use Disorder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further examined the expression of NMU and NMU receptor 2 (NMUR2) in NAc and the dorsal striatum of high compared with low alcohol-consuming rats, as this area is of importance in the maintenance of alcohol use disorder (AUD).
|
31069918 |
2019 |
|
Alcohol Use Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Given that AUD is a major health-care challenge causing an enormous cost to society and novel treatment strategies are warranted, our data suggest that NMU analogues deserve to be evaluated as novel treatment of AUD in humans.
|
26769653 |
2017 |
|
Amnesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to utilize NMU as a clinical treatment tool for inflammation-mediated amnesia, we herein focused on non-invasive intranasal delivery because the i.c.v. administration route is invasive and impractical.
|
29079533 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, NmU may be involved in the HGF-c-Met paracrine loop regulating cell migration, invasiveness and dissemination of PDAC.
|
19118941 |
2009 |
|
Anorexia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects.
|
29057457 |
2018 |
|
Anorexia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The PEGylated NMU-8 showed potent and robust anorectic activity and anti-obesity effect in diet-induced obesity (DIO) mice by once-daily subcutaneous (s.c.) administration.
|
28400225 |
2017 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and non-metastatic human bladder cancer T24 cells and observed increased NMU RNA expression.
|
16878152 |
2007 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter.
|
16878152 |
2007 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The gene expression profiles of the NMU-induced primary tumors were most similar to ER-positive, low to intermediate grade breast cancer.
|
15845649 |
2005 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
An analysis of 3,489 cases of breast cancer showed NmU to be associated with poor patient outcome, particularly those with HER2-overexpressing tumors independent of established prognostic indicators.
|
24876102 |
2014 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, our results report a new mechanism of action for NmU in HER2-overexpressing breast cancer that enhances resistance to HER2-targeted drugs through conferring CSC characteristics and expansion of the CSC phenotype.
|
28340506 |
2017 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, our results report a new mechanism-of-action for NmU in HER2-overexpressing breast cancer that enhances resistance to the anti-tumor immune response.
|
29209569 |
2017 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Next, the biological impact of NMU on breast cancer cells in relation to NMUR2 expression was analyzed.
|
28423716 |
2017 |
|
Breast Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The NMU breast cancer model induced in the rat is used for the study of mammary carcinogenesis because it closely mimics human breast disease.
|
15845649 |
2005 |
|
Cachexia
|
0.010 |
AlteredExpression
|
phenotype |
LHGDN |
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
|
16878152 |
2007 |
|
Cancer cachexia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia.
|
16878152 |
2007 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
To conclude, the results have clearly shown that capsaicin performs a very important defensive role during breast carcinogenesis and has the ability to act as a chemo-suppressive factor against NMU effects.
|
29294454 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Neuromedin U (NMU) activates two G protein-coupled receptors, NMUR1 and NMUR2; this signaling not only controls many physiological responses but also promotes tumorigenesis in diverse tissues.
|
26317338 |
2015 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Neuromedin U (NMU), a neuropeptide isolated from porcine spinal cord and named because of its activity as a rat uterus smooth muscle contraction inducer, is emerging as a new player in the tumorigenesis and/or metastasis of many types of cancers.
|
31492042 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The NMU breast cancer model induced in the rat is used for the study of mammary carcinogenesis because it closely mimics human breast disease.
|
15845649 |
2005 |
|
Carcinoma of bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and non-metastatic human bladder cancer T24 cells and observed increased NMU RNA expression.
|
16878152 |
2007 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer.
|
17018595 |
2006 |